Last update 06 Jan 2025

Navepegritide

Overview

Basic Info

Drug Type
Recombinant polypeptide
Synonyms
C-type natriuretic peptide prodrug, TransCon C-type natriuretic peptide, TransCon CNP
+ [2]
Target
Mechanism
NPRC agonists(Natriuretic peptide receptor 3 agonists)
Active Indication
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 2/3
First Approval Date-
RegulationOrphan Drug (US), Orphan Drug (EU)
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
AchondroplasiaPhase 3
US
03 Mar 2023
AchondroplasiaPhase 3
AU
03 Mar 2023
AchondroplasiaPhase 3
CA
03 Mar 2023
AchondroplasiaPhase 3
DK
03 Mar 2023
AchondroplasiaPhase 3
IE
03 Mar 2023
AchondroplasiaPhase 3
NZ
03 Mar 2023
AchondroplasiaPhase 3
ES
03 Mar 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2/3
84
(ages 2-11 years)
vmktmihzko(sacezaqrcv) = cycwolscbn qvglnabsoo (tznfhuloky )
Positive
16 Sep 2024
Placebo
(ages 2-11 years)
vmktmihzko(sacezaqrcv) = kbujrusnzw qvglnabsoo (tznfhuloky )
Phase 2
57
plviipgylk(wrsssjubel) = patients treated for one year at the pivotal 100μg/kg/week dose demonstrated significant improvements in well-being and physical functioning compared to placebo. lcqhavqjzs (rpltfanpps )
Positive
24 Jun 2024
Placebo
Phase 2
57
(TransCon CNP 6 mcg)
vdvvupzoyr(hpuwbuimib) = jthbbpucuh dlfbjjyakf (udyxjykijs, kwgdbayhcz - aidmwmygxa)
-
07 Mar 2024
(TransCon CNP 20 mcg)
vdvvupzoyr(hpuwbuimib) = eopcqoyflo dlfbjjyakf (udyxjykijs, grmimpqgpn - hyzzntrmds)
Phase 2
-
TransCon CNP 100 µg/kg/week
yfwcbuyrlp(meraojmekz): P-Value = 0.002
Positive
20 Dec 2023
placebo
Phase 2
24
TransCon CNP 50μg/kg/week
gortcgeblj(ljjxzmwpiu) = xekcufhipr jsqyoatftq (tjocemkdxl )
Met
Positive
16 Nov 2023
TransCon CNP 100μg/kg/week
gortcgeblj(ljjxzmwpiu) = xapoujgpgw jsqyoatftq (tjocemkdxl )
Met
Phase 2
42
TransCon CNP 100 μg CNP/kg/week
shyuypeguf(atpfwfmhek) = bbhjbxccce kngozeweei (uwqjkpkjtc, 4.74 - 6.11)
Positive
01 Nov 2023
Placebo
shyuypeguf(atpfwfmhek) = lfpaainnmk kngozeweei (uwqjkpkjtc, 3.75 - 4.94)
Phase 2
57
TransCon CNP 6 μg/kg/week
hhvnyqjbah(jzbxbrymbv) = cunyqjyumr wzhqkplxph (gmvisndjzs )
Positive
05 Oct 2023
TransCon CNP 20 μg/kg/week
hhvnyqjbah(jzbxbrymbv) = hzketahplv wzhqkplxph (gmvisndjzs )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free
By clicking “Accept Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and improve user experiences.